Chimerix Shares Brain Cancer Trial Data

  • Chimerix Inc CMRX has reported topline data from its 50-patient efficacy analysis of ONC201 for recurrent H3 K27M-mutant glioma (a most common type of brain cancer). 
  • ONC201 is an orally administered small molecule dopamine receptor D2 (DRD2) antagonist and caseinolytic protease (ClpP) agonist.
  • An efficacy analysis by blinded independent central review (BICR) of the registration cohort determined the overall response rate (ORR) to be 20.0%. 
  • The median duration of response was 11.2 months, and the median time to response was 8.3 months.
  • One serious adverse event was attributed possibly related to ONC201. Full safety data collection and analysis for this cohort is ongoing. 
  • Prior safety review of ONC201 identified the most commonly reported adverse events as nausea/vomiting, fatigue, and decreased lymphocyte counts.  
  • The Company posted a Q3 EPS loss of $(0.21), missing the consensus of $(0.15) and higher than the loss of $(0.18) a year ago.
  • Chimerix's capital available to fund operations stood at $125 million at the end of Q3.
  • Price Action: CMRX shares closed up 3.74% at $6.10 on Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefsGlioma
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!